Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Attack Rate of COVID-19 Infection in Patients Infected With HIV and/or on Pre-exposure Prophylaxis (PrEP) and Possible Impact of Treatment With an HIV Protease Inhibitor

NCT04379245 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04379245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04379245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Attack Rate of COVID-19 Infection in Patients Infected With HIV and/or on Pre-exposure Prophylaxis (PrEP) and Possible Impact of Treatment With an HIV Protease Inhibitor
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Completed
Start date
April 30, 2020
Completion date
May 4, 2020
Enrollment
4,200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, pre-exposure prophylaxis